Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 07-2024 | 04-2024 | 01-2024 | 10-2023 | 07-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,081 | 710 | 120 | 1,641 | 808 |
| Receivables | 54 | 88 | 64 | 69 | 62 |
| TOTAL | $1,456 | $1,111 | $306 | $1,854 | $996 |
| Non-Current Assets | |||||
| PPE Net | 33 | 34 | 38 | 41 | 33 |
| TOTAL | $33 | $34 | $38 | $41 | $33 |
| Total Assets | $1,489 | $1,145 | $344 | $1,895 | $1,029 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 855 | 1,090 | 603 | 1,273 | 493 |
| Accrued Expenses | 724 | 365 | N/A | N/A | 383 |
| Other current liabilities | N/A | 50 | N/A | N/A | 998 |
| TOTAL | $1,579 | $1,505 | $603 | $1,273 | $1,874 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | -1 |
| TOTAL | $0 | $0 | $0 | $0 | $-1 |
| Total Liabilities | $1,579 | $1,505 | $603 | $1,273 | $1,873 |
| Shareholders' Equity | |||||
| Common Shares | 158,572 | 156,477 | 154,754 | 154,754 | 152,068 |
| Retained earnings | -210,671 | -205,393 | -203,563 | -202,661 | -201,407 |
| Other shareholders' equity | 4,649 | 2,000 | 2,485 | 3,719 | 4,358 |
| TOTAL | $-90 | $-360 | $-259 | $622 | $-844 |
| Total Liabilities And Equity | $1,489 | $1,145 | $344 | $1,895 | $1,029 |